Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1787 | Thyroid cancer | ICEECE2012

Simultaneous occurrence of BRAF mutation and RET/PTC rearrangement is frequent in papillary thyroid carcinoma

Guerra A. , Marotta V. , Di Stasi V. , Volpe A. , Murino A. , Di Stasi M. , Vitale M.

Context: Initial studies reported that RET rearrangements, RAS mutations and BRAF mutation are mutually exclusive genetic events in papillary thyroid carcinoma (PTC). Subsequently, simultaneous occurrence of BRAF mutation and RET/PTC or H4-PTEN has been described in few PTC cases, indicating that these genetic alterations might coexist in PTC in the same cell or in different cells, at least sporadically. In light of the recent finding that frequently BRAF mutation is present o...

ea0029p1797 | Thyroid cancer | ICEECE2012

Papillary thyroid carcinoma with high percentage of BRAFV600E alleles have a higher recurrence rate

Guerra A. , Fugazzola L. , Marotta V. , Cirillo M. , Di Stasi V. , Volpe A. , Murino A. , Di Stasi M. , Vitale M.

Context: Although unexplained conflicting results are present in the literature, most of studies report the association of BRAFV600E in papillary thyroid carcinoma (PTC) with a more advanced disease and with a worst prognosis. We recently demonstrated that in most of the cases PTC consists of a mixture of tumour cells with wild-type and mutant BRAF. Hence, we examined the association of percentage of BRAFV600E alleles with clinicopathologic parameters at diagnosis and disease ...

ea0029p1509 | Pituitary Clinical | ICEECE2012

Efficacy of testerone 2% gel replacement therapy on erectile function, muscle strenght and general wellbeing in men affected by normo-hypogonadotropic hypogonadism

Lo Calzo F. , Galdiero M. , Vitale P. , Cariati F. , Cozzolino A. , Grasso L. , Colao A. , Pivonello R.

Background: Hypogonadism is a clinical entity characterized by low serum testosterone (T) levels associated with several clinical signs and symptoms which can negatively affect the quality of life. T replacement therapy (TRT), restoring serum T concentrations, improves signs and symptoms related to hypogonadism. Many T formulations are presently available. The aim of the study was to assess effects of 2% gel TRT on serum T concentrations, erectile function, muscle strength and...

ea0011oc8 | Signal transduction OC1 Novartis Oncology Young Investigator Award | ECE2006

Role of the calcium-calmodulin dependent kinase II in oncogenic Ras-induced proliferation

Cavallo AL , Illario M , Di Vito E , Monaco S , Fenzi G , Rossi G , Vitale M

Activation of the Ras/ERK pathway and stimulation of proliferation by integrins in thyroid cells requires CaMKII activation. To date, whether this role of CaMKII is a general mechanism or is restricted to integrin signalling is unknown. As oncogenic activation of the Ras/ERK pathway by mutated Ras, RET/PTC and Trk is frequent in papillary thyroid carcinoma (PTC), we investigated the expression and activation level of CaMKII in PTC primary culture and in stable cell lines.<...

ea0029p779 | Endocrine tumours and neoplasia | ICEECE2012

Sorafenib stops disease progression in the majority of patients with advanced differentiated thyroid cancer refractory to radioactive iodine.

Marotta V. , Ramundo V. , Del Prete M. , Marciello F. , Palmieri G. , Camera L. , Vitale M. , Colao A. , Faggiano A.

Differentiated thyroid cancers (DTC) have an excellent prognosis with a 10 year disease-related survival of 85%. However, about 5% of DTC patients develop an aggressive disease with distant metastasis and loss of radioactive iodine (RAI) avidity. An effective treatment is not available for these patients and survival rates are less than 15%. The MAP-kinase pathway is strikingly involved in the pathogenesis of DTC. This is why compounds striking the MAP-Kinase pathway may be us...

ea0029p836 | Endocrine tumours and neoplasia | ICEECE2012

Vitamin D from genetics to the clinical in prostate cancer

Cariati F. , Negri A. , Pivonello C. , Ferro M. , Sarnataro M. , Terracciano D. , Galdiero M. , Vitale P. , Altieri V. , Colao A. , Pivonello R.

Background: The prostate cancer (CaP) is among the most commonly diagnosed cancers, accounting for about 20% of all newly diagnosed cancers. Subject of recent studies is the role of vitamin D in the pathogenesis of CaP. Literature data speculated about the role of vitamin D in the progression of Cap. In addition, several studies have shown an association between VDR gene polymorphism FokI and CaP especially in the Asian population.Objective: The aim of t...

ea0029p1394 | Pituitary Clinical | ICEECE2012

Evaluation of ejaculatory function in acromegalic men: preliminary study

Galdiero M. , Vitale P. , Grasso L. , Lo Calzo F. , Cariati F. , Lotti F. , Maggi M. , Colao A. , Pivonello R.

Introduction: Acromegaly is a systemic disease frequently characterized by hypogonadotropic hypogonadism, endothelial dysfunction and diseases classically associated with an increased incidence of erectile dysfunction (ED) (hypertension, dyslipidemia, impaired glucose metabolism) and premature ejaculation (prostatic disease). Furthermore, the high prevalence of ED may negatively affect ejaculatory function. The purpose of this study was to evaluate the ejaculatory function of ...

ea0029p1395 | Pituitary Clinical | ICEECE2012

Evaluation of male sexual function in active acromegalic patients and after disease remission: preliminary study

Galdiero M. , Vitale P. , Grasso L. , Lo Calzo F. , Cariati F. , Lotti F. , Maggi M. , Colao A. , Pivonello R.

Introduction: Acromegaly is frequently characterized by hypogonadotropic hypogonadism, endothelial dysfunction, hypertension and impaired glucose and lipid metabolism, classically associated with impaired sexual function (SF). There are no literature data on the SF in acromegaly. The purpose of this study was to evaluate the SF of patients with acromegaly.Patients and methods: Twenty-two patients (47.8±8.6 years) were enrolled into the study. Among ...

ea0026p624 | Clinical case reports | ECE2011

17β-hydroxysteroid dehydrogenase type 3 deficiency: a new case of a rare disease with an uncommon gene mutation

Galdiero M , Vitale P , Cariati F , Grasso L F S , Cozzolino A , Simeoli C , Afeltra L , Piscopo C , Rossi R , Melis D , Alviggi C , Lombardi G , Colao A , Pivonello R

Deficiency of 17β-hydroxysteroid dehydrogenase type 3 (17βHSD3), an enzyme converting androstenedione (A) to testosterone (T) in the Leydig cells of the testis, is a rare cause of autosomal recessive 46,XY disorders of sexual development (DSD). A 18-year-old phenotypically female patient presented with primary amenorrhea. She had deep voice, macrocephaly, broad forehead, enlarged nasal tip, macrostomia, facial acne, gynecomastia, left-convex dorsal scoliosis, hypopla...

ea0029p1366 | Pituitary Clinical | ICEECE2012

An insight into the mechanisms underlying the sympathoinhibition of acromegaly

Carzaniga C. , Seravalle G. , Attanasio R. , Grassi G. , Lonati L. , Facchini C. , Cozzi R. , Fatti L. , Montini M. , Vitale G. , Sciortino G. , Damanti S. , Brambilla G. , Cavagnini F. , Mancia G. , Scacchi M. , Persani L.

By direct measurement of muscle sympathetic nerve activity (MSNA) we previously demonstrated a markedly decreased adrenergic tone in newly diagnosed acromegalic patients. The present study was aimed at confirming this finding in a larger group of patients and establishing the pathophysiological role of insulin resistance, GH and IGF1 levels, circulating leptin and extracellular water (ECW) in this abnormality.Study design: Fifteen de novo patients...